8-K: Absci Corporation Reports First Quarter 2024 Financial Results and Business Updates

Absci Corporation announced its first quarter 2024 financial results, highlighting progress in its internal pipeline and drug creation partnerships.

Summary

• Absci Corporation reported a revenue of $0.9 million for the first quarter of 2024, a decrease from $1.3 million in the same period of 2023.
• The company's research and development expenses were $12.2 million, slightly down from $12.7 million in the first quarter of 2023.
• Selling, general, and administrative expenses decreased to $8.7 million from $9.6 million year-over-year.
• Absci's net loss for the quarter was $22.0 million, compared to a net loss of $23.4 million in the first quarter of 2023.
• The company's cash, cash equivalents, and short-term investments totaled $161.5 million as of March 31, 2024, up from $97.7 million at the end of 2023.
• Absci completed a public offering of common stock in March 2024, raising approximately $86.4 million in gross proceeds.
• The company expects a gross use of cash of approximately $80 million for the fiscal year ending December 31, 2024.
• Absci believes its current cash reserves will fund operations into the first half of 2027.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant progress in the pipeline and a successful capital raise, although there are some financial losses and risks associated with drug development.

Positives

• Absci successfully raised $86.4 million through a public offering, strengthening its financial position.
• The company is making significant progress in its internal pipeline, with ABS-101 advancing to IND-enabling studies.
• Absci has a strong cash position of $161.5 million, expected to fund operations into the first half of 2027.
• The company is actively pursuing new drug creation partnerships, with at least four expected in 2024.
• Absci is focused on advancing its internal pipeline and partnered programs while improving platform and operational efficiencies.

Negatives

• Revenue decreased to $0.9 million in Q1 2024 from $1.3 million in Q1 2023.
• The company reported a net loss of $22.0 million for the first quarter of 2024.
• Absci expects a gross use of cash of approximately $80 million for the fiscal year ending December 31, 2024.

Risks

• The company's success is dependent on obtaining and maintaining necessary approvals from the FDA and other regulatory authorities.
• There is a risk that positive results from preclinical studies may not be replicated in clinical trials.
• Absci relies on third parties for manufacturing and supply of preclinical and clinical materials.
• The company's ability to collaborate effectively with partners is crucial for its success.
• Market conditions and regulatory developments could affect the company's activities and partnerships.

Future Outlook

Absci anticipates initiating Phase 1 clinical studies for ABS-101 in early 2025 and expects to advance at least one additional internal asset program to a lead stage in 2024. The company also expects to sign additional drug creation partnerships with at least four partners in 2024 and believes its current cash reserves will fund operations into the first half of 2027.

Management Comments

• Sean McClain, Founder and CEO, stated that the company made significant strides in advancing both internal and partnered programs.
• Sean McClain expressed excitement about the progress, highlighting the potential of their generative AI platform to disrupt drug discovery.

Industry Context

Absci's focus on generative AI for drug creation aligns with the growing trend of leveraging artificial intelligence in the pharmaceutical industry to accelerate drug discovery and development. The company's pipeline targets areas with significant unmet medical needs, reflecting a broader industry focus on developing innovative therapies.

Comparison to Industry Standards

• Absci's approach of using generative AI for drug discovery is comparable to companies like Recursion Pharmaceuticals and Insitro, which also leverage AI for drug development.
• The company's focus on biologics development is similar to companies like Regeneron and Amgen, which are leaders in the antibody therapeutics space.
• The $86.4 million capital raise is a significant amount for a company at this stage, but is not unusual for biotech companies developing novel therapeutics.
• The expected cash burn of $80 million for the year is typical for a company in the clinical development phase, and the cash runway into 2027 is a positive sign for investors.

Stakeholder Impact

• Shareholders will be impacted by the financial results and the progress of the company's pipeline.
• Employees will be impacted by the company's continued operations and growth.
• Customers and partners will be impacted by the company's progress in drug creation and development.
• Creditors will be impacted by the company's financial stability and cash position.

Next Steps

• Absci plans to share additional preclinical data for ABS-101, including data from non-human primate studies, in the next few months.
• The company plans to share additional information for ABS-201 and ABS-301 in the second half of 2024.
• Absci expects to initiate Phase 1 clinical studies for ABS-101 in early 2025.
• The company anticipates selecting a development candidate for ABS-201 in the second half of 2024.
• Absci expects to complete mode-of-action validation studies for ABS-301 in the second half of 2024.
• Absci plans to advance at least one additional internal asset program to a lead stage in 2024.
• The company anticipates signing additional drug creation partnerships with at least four partners in 2024.

Key Dates

Keywords

AI drug creation, biologics, antibody, generative AI, drug discovery, clinical trials, preclinical studies, partnerships, ABS-101, ABS-201, ABS-301